Dr. Javier Del Pino is Associate Professor at the Department of Pharmacology and Toxicology, University Complutense of Madrid, Spain from 2016. He received his PharmD degree at the University Complutense University of Madrid in 2004. He has two Masters in Sciences 2009 and 2010. He worked in Institute of Health Carlos III in the National Center of Environmental Health. From 2010 to 2012 he was an Associated Researcher at University of Massachusetts (UMASS) working in Sandra Petersen´s Lab in a National Institute of Health (NIH) project on developmental effects of TCDD endocrine disruptor on sexual differentiation. He specialized in neurotoxicology and neurodevelopmental toxicology and received his Ph.D. in Toxicology in 2009. He is a member and Manager of the Complutense University’s Research Team EcoBioTox. He is a co-author of several publications on toxicology and environmental journals and participated as a co-author of toxicology Book´s chapters.

Dr. Del Pino research focuses on the evaluation of the effects of environmental pollutants in the development of neurodegenerative diseases. His area of expertise is neurotoxicology, cytotoxicity, and toxicogenomics since his research deepens into the toxic effects of metals and biocides that induce cognitive disorders and other neurodegenerative processes both at cellular and tissue level, studying the molecular mechanisms involved in these effects. He takes a special interest in the genomic toxic effects that metals and biocides produce and the levels from which these effects are produced, all related to the safety evaluation of these compounds.

Silvio De Flora, MD, PhD, was assistant Professor (1966), full Professor and chairman (1975), and Professor emeritus (2012) at the School of Medicine of the University of Genoa (Italy), where he was director for 22 years of the Institute of Hygiene and Preventive Medicine (1986-1998) and of the Department of Health Sciences (1999-2005 and 2010-2012). Author of 460 full length papers, 308 of which available in PubMed. The overall impact factor is 1500. With almost 14,000 citations, the h-index is 58. He published in collaboration with 140 laboratories in European countries, China, Japan, India, New Zealand and USA. Member of the editorial board of 16 international journals. Principal investigator of a number of research projects, 10 of which awarded by the US NIH. He received several honors, among which the award from the Michigan State University (2002), the Sobels Award (Greece, 2005), and dedication of 10th ICMAA (Brazil, 2010).

His research interest was focused on epidemiology and prevention of viral diseases until 1975. Thereafter he investigated several topics related to genomics, environmental mutagenesis and prevention of cancer and other chronic degenerative diseases, including chemoprevention of cancer and modulation of molecular biomarkers

Stefano BONASSI, born on January, 3, 1956 is a Doctor in Biological Sciences - University of Genova and a Specialist in Medical Statistics and Epidemiology - University of Pavia. He is a Faculty for PhD programs in human genetics of the Universidad Autonoma de Barcelona, Barcelona, Spain, and M2E2 International courses of Molecular Epidemiology of Chronic diseases at the Maastricht University, the Netherlands . He is a reviewer of many Journals such as Experimental Research; Mutagenesis; Cancer Epidemiology, Biomarkers & Prevention Et al.

Stefano BONASSI is interested in the use of biomarkers in human population and clinical studies. He studied chromosomal damage in the early stages of carcinogenesis and other chronic diseases. He coordinated the epidemiological part of international projects, such as ESCH on chromosome

Giovanni Pagano graduated in Biological Sciences in 1971 at Naples University and at the International Institute of Genetics and Biophysics in Naples. He served the Italian National Cancer Institute in Naples up to retirement in 2005, with a major focus on environmental toxicology. In recent years GP has collaborated with a number of national and international institutions, and lecturing at several post-graduate courses. The current positions are Research Contractor at Federico II University, and Associate Researcher at the Stazione Zoologica Anton Dohrn. GP authored over 100 publications receiving over 2000 citations; ResearchGate Score 36.63.

His research interests mainly lies in the fields of Aquatic Ecotoxicology, Genotoxicity, Biomarkers and Cytogenetics

Boris A. Katsnelson, born in 1926 (October 20) in Lugansk, Ukraina is the Head of Department of Toxicology and Biological Prophylaxis at the the Ekaterinburg Medical Research Center for Prophylaxis & Health Protection in Industrial Workers. He graduated from Сhelyabinsk State Medical College (Russia) in 1949 as a GP and received postgraduate training in occupational medicine in the same year at the Central Institute for the Postgraduate Medical Education (Moscow). During 1949 – 1954 he worked as an industrial sanitary inspector and occupational health specialist in different state agencies in Chelyabinsk. In 1954 - 1957 he received postgraduate scientific training (as a PhD student) in occupational medicine at the Moscow Institute of Industrial Hygiene and Occupational Diseases of the USSR Academy of Medical Sciences. He recently worked in the Sverdlovsk Research Institute of Industrial Hygiene and Occupational Diseases later on reorganized into the Ekaterinburg Medical Research Center.

Boris A. Katsnelson's research interest includes silicosis; pulmonary particles and nanoparticles clearance and physiologically oriented modeling of the process; toxicology with special interest in combined toxicity & nanotoxicology; occupational exposure limits for fibrogenic and toxic substances; bioprotectors against adverse health effects of occupational/environmental toxic exposures; predisposition to occupational and environmentally conditioned diseases; socioeconomic aspects of occupational and environmental medicine; occupational & environmental epidemiology

Mohamed Abou-Donia is currently working as a Professor of Pharmacology & Cancer Biology at the Duke University Basic Science Departments. He obtained his Ph.D., University of California at Berkeley 1967. He also worked as a Professor in Neurobiology, Neurobiology, Basic Science Departments. He was honored in 2004 with the Traditional Fulbright Scholarship. Council for International Exchange of Scholars.

His research interest mainly lies in understanding the basic mechanisms by which chemicals adversely affect the nervous system, which should lead to a better assessment of acute and chronic neurotoxicities and the development of drugs to prevent or treat them. His recent publications include Autoantibodies to nervous system-specific proteins are elevated in sera of flight crew members: biomarkers for nervous system injury and many such sublime ones.

Diana Anderson holds the Established Chair in Biomedical Sciences at the University of Bradford. She obtained her first degree in the University of Wales and second degrees in the Faculty of Medicine, University of Manchester. She has over 450 peer-reviewed papers, 8 books, has successfully supervised 26 PhDs, and been an Editorial Boards Member of 10 international journals. She has been or is Editor in Chief of a book Series on toxicology for J. Wiley and sons and the Royal Society of Chemistry respectively. She gives key note addresses at various international meetings. She is a consultant for many international organisations, such as the WHO, NATO, TWAS, UNIDO and the OECD.

Her Research Interests Includes: cancer, oxygen radicals, human biomonitoring, unbalanced precursor pools, dietary imbalance, male-mediated developmental defects, nanotoxicology and general toxicology

Eva Cecilie Bonefeld-Jørgensen (ECB-J), Professor in Human Environmental Toxicology and Director of Center for Arctic Health (http://www.cah.au.dk/) has been the head of the research group (1 part-time professor, 1 associated professor, 1 post doc, 4 PhD students, 1 research assistant, 2 research year stud. med, 2 student assistants, 2 technical assistant, 2 thesis research student) for more than 18 years and has more than 15 years of experience in the research area of human toxicology and endocrine disruptors. ECB-J has a formal education as research leader.

Her Research Interests Include: Health and Illness , Research and Examination Methods , Environment and industrial medicine Arctic Environmental Medicine Cellular & Molecular Toxicology Endocrine disrupting chemicals Environmental chemicals thyroid hormone disruption. Health and Illness, Research and Examination Methods, Molecular medicine Arctic Environmental Medicine Mechanistic Epidemiology International Cohort studies

Marcelo L. Larramendy, Ph.D., serves as Professor of Molecular Cell Biology at the School of Natural Sciences and Museum (National University of La Plata, Argentina). Appointed Senior Researcher of the National Scientific and Technological Research Council of Argentina. Former Member of the Executive Committee of the Latin American Association of Environmental Mutagenesis, Teratogenesis and Carcinogenesis. Author of more than 470 contributions, including scientific publications, research communications and conferences worldwide. Recipient of several national and international awards. Prof. Larramendy is a regular Lecturer at the international A. Hollaender Courses organized by the IAEMS and former guest scientist at NIH (USA) and University of Helsinki, (Finland). He is expert in Genetic Toxicology and is, or has been, referee for more than 30 international scientific journals. Member of the International Panel of Experts at the International Agency for Research on Cancer (IARC, WHO, Lyon, France) in 2015 for the evaluation of DDT, 2,4-D and Lindane. Presently, Prof. Dr. Larramendy is Head of the Laboratory of Molecular Cytogenetics and Genotoxicology at the UNLP.

Marcelo L. Larramendy’s fields of research interest include genotoxicity, Teratogenesis and Carcinogenesis. His areas of expertise include Molecular Cytogenetcis, Genetic Toxicology and Ecotoxicology.

Myung-Haing Cho has completed his Ph.D in Toxicology from the University of California, Davis, USA and his M.S in Vet. Toxicology from Seoul National University, Korea. At present he is serving as a President of Korean Society of Toxicology. He is also a member at the Science and Technology Commission of Food, Agriculture, Forestry and Fisheries,Ministry for Food, Agriculture, Forestry and Fisheries, Korea.

His Research interests are mainly into the field of Toxicology, Veterinary Toxicology, Nanoparticles and Nanotechnology

Vesna Matović has completed her BSc Pharm, University of Belgrade, MSc Pharm in Toxicological chemistry at the University of Belgrade. She has done her PhD Pharm in Toxicological chemistry at the University of Belgrade. She is now serving as a Professor at Department of Toxicology “Akademik Danilo Soldatović” Faculty of Pharmacy, University of Belgrade

Her research interests include: Toxicology and ecotoxicology of metals, Interactions between heavy metals and bioelements, Toxicology and ecotoxicology of persistent organic pollutants, Mechanisms of toxicity, Oxidative stress induction and Toxicology of Mixtures.

María Concepción Gutiérrez Rui has completed her Degree in Chemistry from the Universidad Iberoamericana (1976) and her Masters of Experimental Biology at the UAM (1980). She obtained her Doctorate in Pharmacology in Research Center and Advanced Studies. She is serving as a National level III Investigator.

Her Research Interest Includes: Health Sciences, Cellular and molecular mechanisms, Pharmacology and Toxicology

Friday EUboh completed his PhD from University of Calabar, Calabar, Nigeria, and is presently an Associate Professor of Biochemistry, with Toxicology as his area of research interest. He served as the acting Head of Biochemistry Department in the Department of Biochemistry University of Calabar, Calabar, Nigeria, from 2011 to 2013. He is a member of Nigerian Society of Biochemistry and Molecular Biology, and Institute of Public Analysts of Nigeria. He has more than 60 papers published in reputable Journals, and is a reviewer and Editorial Board Member of many Journals of repute. He has also presented many conference papers, locally and internationally.

His Research interests include Biochemistry, Toxicology and Molecular Biology, Toxicology being his main focus.

Professor at Zhejiang University Institute of Respiratory Diseases, China,Hangzhou Songmin Ying was a Postdoctoral Research Scientist at the University of Oxford • Gray Institute for Radiation Oncology and Biology. He was also a Cancer Research UK China Fellow at the University of Oxford • Weatherall Institute of Molecular Medicine. He obtained his PhD from Technische Universität München Institut für Medizinische Mikrobiologie, Immunologie und Hygiene.

His fields of Research Interests Includes: Cell biology, Cancer Research, Immunology, Oncology, Infectious Diseases and Respiratory Medicines.

Omid Sabzevari (OS) is a scientist in the field of Mechanistic Toxicology and Pharmacology, Xenobiotics Analysis and Food Safety. OS was listed among Top 1% Scientists of the World according to ESI/ISI in May 2012. OS is a Temporary Adviser of WHO and a scientific member of the Expert Panel on Food Safety, JECFA. OS is President of Iranian Association of Pharmaceutical Scientists (IranAPS) and President of Iranian Society of Toxicology (IranTox). He is also the Head of Basic and Clinical Toxicology Research Centre, TUMS.

His research interests include Toxicology: Molecular Toxicology, Drug Metabolism, Hepatotoxicity, Analytical/Forensic Toxicology, Management of Poisoning and Drug Overdose: Hallucinogenics, NSAIDs, Narcotics, Opioids, Drug of Abuse Pharmacology: Pharmacokinetic, Biotransformation,, Drug Interactions, Vasoactive Peptides, Diuretics, Opioids, Endocrine Hormones, Antifungal Drugs, Drug of Abuse

Dr. Thomas Slaga has more than 45 years of experience in studying the mechanisms of carcinogenesis and chemoprevention and directing and establishing research centers. He is currently a Professor in the Department of Pharmacology, Associate Director for Basic Research of the NCI designated Cancer Center, Director of the Texas Consortium of Chronic Disease Prevention and Director of the Regional Health Science Center at Edinburg. Dr. Slaga started an active leadership role when he became head of an interactive research program on carcinogenesis and chemoprevention at the Oak Ridge National Laboratory. Later he became Director of the UTMDACC-SP whose mission was multidisciplinary and interactive research on cancer causation and prevention. Dr. Slaga became Scientific Director at the AMC Cancer Research Center and Deputy Director of the University of Colorado Comprehensive Cancer Center. Dr. Slaga has an important leadership role nationally and internationally in carcinogenesis and cancer prevention having started the Journal of Molecular Carcinogenesis. He has served on many review committees such as a full member and chair of the Chemical Pathology Study Section, American Cancer Society review groups, Cancer Center review groups and program project review committees. He also served on several NIEHS, EPA and FDA review committees. Dr. Slaga also serves on the Board of Directors for the Aspen Cancer Conference and several scientific advisory committees. He has a very active and funded research program. Continuously funded since 1974, his research program is currently supported by several R01 grants. He has over 300 peer reviewed publications and over 200 invited review articles, book chapters and scientific books on cancer as well as a lay book entitled, "The Detox Revolution" which emphasizes the importance of diet, nutrition and phytonutrients in chronic disease prevention.

The research in Dr. Thomas Slaga's laboratory is focused on glucocorticoid hormones (GC), very potent inhibitors of physiological DNA synthesis in keratinocytes in vivo. These hormones are also very effective in preventing carcinogen- and tumor promoter-induced skin hyperplasia, inflammation, and mouse skin tumor formation when applied to skin together with a carcinogen or a tumor promoter. We and others have shown, however, that the GC do not affect the growth of either established papillomas, squamous cell carcinomas (SCC), or transformed keratinocytes in vitro. In addition, we recently found that the GC do not affect glucocorticoid-responsive genes in transformed keratinocytes both in vitro and in vivo. We have generated skin-targeted transgenic mice over-expressing the GR under the control of the keratin 5 (K5) promoter. These adult transgenic mice have impaired proliferative and inflammatory responses to skin tumor promoters. Our initial studies showed that the K5.GR transgenic animals are resistant to ras-induced tumorigenesis. The constitutively nuclear overexpression and activation of the GR in the epidermis dramatically inhibited skin tumor development in K5.GR/ras+ double transgenic mice in terms of number of animals that develop tumors, number of tumors per animal, and tumor size. In another study we plan to determine the mechanism(s) of synergistic action of the natural source compounds, known to inhibit one or more stages of skin carcinogenesis, i.e., initiation and promotion/progression. The concurrent topical and systemic (i.e., dietary) treatment with selected natural source inhibitors of different stages of skin carcinogenesis result in synergistic effects leading to more efficient prevention of skin cancer. The natural source inhibitors to be tested include ellagic acid, imperatorin from the family of coumarins, proanthocyanidin B-2-gallate, (-)-epigallocatechin from the family of green tea polyphenols, N-acetylcysteine, calcium D-glucarate, lycopene, carnosol and ursolic acid from rosemary extract, and resveratrol. We propose to initially utilize a number of very predictive short-term in vitro and in vivo tests in order to identify the mechanism(s) and to differentiate the potencies of selected inhibitors at various concentrations under standard conditions. The most effective compounds will then be studied in long-term tumor experiments utilizing a 7,12-dimethylbenz[a]anthracene (DMBA)-induced 12-O-tetradecanoylphorbol-13-acetate (TPA)-promoted multistage carcinogenesis model in SENCAR mice.

Dr. Mohamed Abou-Donia is a Professor of Pharmacology and Cancer Biology at Duke University Medical Center. He also holds a secondary appointment as a Professor of Neurobiology. He has been the Director of the Neurotoxicology Laboratory at Duke University Medical Center (1975-present). He was the Deputy Director of the Toxicology Program at Duke University from 1981 to 1995. He obtained his Ph.D. from the University of California at Berkeley. He is a Certified Toxicologist by both the American Board of Toxicology since 1981 and the Academy of Toxicological Sciences since 1982. The overall research program in his laboratory is directed toward understanding the basic mechanism by which chemicals, e.g., pesticides, solvents, industrial chemicals, heavy metals, drugs, and nerve agents, adversely the nervous system. He has been investigating the mechanisms involved in the Persian Gulf War Veterans’ Illnesses and developing treatment for them. His research program has focused on the assessment of brain injury from chemicals and trauma and developing serum biomarkers for such injuries. (e.g. J. Toxicol. Environ Health 76:363-380.). His research program has been funded by private organizations, e.g., Rockefeller Foundation and World Health Organization and federal agencies including NIESH, NIOSH, EPA, USDA, and DOD. He has more than 300 peer reviewed publications, most of which are in the area of neurotoxicology and edited a book “Neurotoxicology”.

Organophosphorus compounds (Ops) induce neurodegenerative disorders. This action is related to their ability to phosphorylate target proteins. Ops have three distinct actions: 1) Cholinergic neurotoxicity resulting from inhibition of acetylcholinesterase (AChE), 2) Organophosphorus ester-Induced Delayed Neurotoxicity (OPIDN), and 3) Organophosphorus ester-Induced Chronic Neurotoxicity (OPICN). Our recent studies using gene expression of rat brain, 15 min and 3 months after exposure to sarin, elucidated the sarin-induced neurotoxicity. A lethal dose of sarin caused up-regulation of nicotinic, muscarinic, GABAnergic and glutamergic receptors, consistent with the activation of glutamate receptors leading to the release of l-glutamate amino acid and activation of NMDA receptor resulting in massive Ca2+ influx and neuronal cell death. Calcium calmodulin kinase II was up-regulated in brain regions that are sensitive to OPIDN. This enzyme that is involved with glutamate receptors in the process of learning and memory is activated by Ca2+ influx through NMDA receptors resulting in mitochondrial dysfunction and free radical formation, followed by caspase activation and apoptotic cell death.

Dr. Costa has been working in the area of epigenetics and cancer for over 20 years. He has studied how carcinogenic metals affect the epigenetic program through inhibition of histone demethylases. In particular, Dr. Costa has studied how Arsenic, Nickel and Chromate alter histone posttranslational modifications in chromatin using cell culture and in human PBMCs. Dr. Costa has also conducted ChIP-Seq using several histone marks and RNA-Seq following carcinogenic metal treatment of cells. He has been working on the mechanism of metal carcinogenesis for over 35 years.

Environmental Medicine, Genotoxicity, Toxicology, Pharmacology,Oncology

Raghbir Athwal has done his BSc Biology, MSc Genetic at the Punjab Agricultural University. He completed his PhD in Genetics at the University of Missouri. Dr. Raghbir Athwal has done his Postdoctoral fellowship in the Division of Human Genetics, Department of Pediatrics at the University of Missouri and in the Laboratory of Biochemistry at the Howard University Medical School. Dr. Raghbir Athwal has been research associate National Institutes of Health, National Cancer Institute. Currently, Dr. Raghbir Athwal is working as a Professor in the department of Pathology and Laboratory Medicine at the Temple University School of Medicine and Fels Institute for Cancer Research and Molecular Biology

The long term goal of our research is to elucidate molecular and genetic pathways involved in the regulation of normal cell growth leading to senescence, and their role in the development of cancer and cellular aging. Normal mammalian cells, unlike cancer cells, multiply only for a finite number of generations, and eventually enter a state of irreversible growth arrest, “the replicative senescence”. Applying a functional strategy, we have identified four cell senescence genes, three on chromosome 6q and one on 16q. The ectopic expression of one of the genes (SEN6A), cloned in a retroviral vector, induce senescence in ovarian and breast tumor cells, and lead to premature senescence in normal human fibroblasts. SEN6A is either rearranged or not expressed in many of the breast and ovarian tumor cells, suggesting that it plays a role in the etiology of breast and ovarian cancers. Further pursuit of our research includes delineation of mechanisms of SEN6A inactivation in tumor cells; and identifies signaling pathways involved in the functioning of SEN6A. Our preliminary observations revealed that SEN6A may be involved in DNA damage-repair response through a pathway related to the production of Reactive Oxygen Species (ROS). These finding evoked our interest to study genes associated with DNA damage – repair pathways in relation to cellular senescence. Signaling pathways that regulate cell senescence has gained significance as emerging targets for cancer therapy. In another project, we are investigating the molecular mechanisms of virus induced malignant transformation of human cells. These studies are driven by the hypothesis that immortalization of human cells requires the disruption of specific genes through viral integration. Using SV40 mediated immortalization of human fibroblasts as a model system; we have isolated a human DNA segment, corresponding to the viral insertion site. The introduction of this cloned human DNA segment, into SV40 immortalized cells, led to the restoration of normal cell growth pattern and senescence. Almost 100 percent of cervical cancer is positive for the presence of HPV virus. Future studies in this project are directed to identify human genes disrupted through HPV integration, and examine their role in the etiology of cervical cancer. The ultimate aim of our research is to identify molecular targets for diagnosis and therapeutic intervention of cancer.

Dr. Mustafa I. Selim is currently working as Professor in the Department of Pharmacology and Toxicology at the Brody School of Medicine at East Carolina University. Dr. Mustafa I. Selim expertise in Toxicology, Biochemistry, Environmental Chemistry, Pharmacology

Research in Dr. Selim's laboratory is focused on two areas: 1) investigating the toxic and detoxification mechanisms of hazardous and cancer causing chemicals, such as pesticides and mycotoxins (particularly aflatoxin B1), with the goal of developing technology for treatment or mitigation of exposure to such chemicals.2) method development and application of modern analytical techniques (e.g. SFE, GC/MS & LC/MS) for studying: the effect of air pollutants on cardiovascular and upper respiratory diseases; assessing the health effects of human exposure to toxic and endocrine disrupting chemicals in drinking water, foods, dietary supplements, and consumer products.

Amr Amin has completed his PhD at University of Illinois at Chicago, and received a post-doctoral training in the field of molecular genetics at the University of Pennsylvania School of Medicine. He started his academic career at UAE University where he serves now as a Full Professor of Cell Biology. Amr’s research focuses on ways to control cancer, particularly liver cancer. He published many research articles and reviews and serves as reviewer and as an editorial member of many specialized peer-reviewed journals. He is also a member of many specialized societies and the sole recipient of multiple national and international scientific awards.

Biological application of nanotechnology Biological applications of MRI and CT Cancer Biology Cell Biology Preventive medicine

Alexei Basnakian received his PhD and DSc degrees from the Russian Academy of Medical Science, both in the field of DNA endonucleases. He had postdoctoral trainings in molecular biology at the Harvard Medical School and in toxicology/cancer research at the National Center for Toxicological Research. Dr. Basnakian is Professor in the Department of Pharmacology and Toxicology, and Director of the DNA Damage and Toxicology Core Center at the University of Arkansas for Medical Sciences, and Research Career Scientist at the Veteran’s Hospital in Little Rock, Arkansas, USA. He is an author of more than 85 peer-reviewed papers and 12 reviews or book chapters. Dr. Basnakian is an Editorial Board member of several biomedical journals, and a member of NIH and VA grant study sections. His research interests are in DNA endonucleases and DNA damage associated with toxicity, anti-cancer therapy, cell injury and cell death.

DNA endonucleases and DNA damage associated with toxicity, anti-cancer therapy, cell injury and cell death.

At the NCL, Dr. Dobrovolskaia directs characterization related to a nanomaterials' interaction with components of the immune system. She monitors acute/adverse effects of nanoparticles as they relate to the immune system, both in vitro and in animal models. Dr. Dobrovolskaia is also responsible for the development, validation and performance qualification of in vitro and ex vivo assays to support preclinical characterization of nanoparticles, and for monitoring nanoparticle purity from biological contaminants such as bacteria, yeast, mold and endotoxin. Additionally, she leads structure activity relationship studies aimed at identifying the relationship between nanoparticle physicochemical properties and their interaction with macrophages, components of the blood coagulation cascade, and complement systems. Prior to joining the NCL, Dr. Dobrovolskaia worked as a Research Scientist in a GLP laboratory at PPD Development, Inc. in Richmond, VA. She was responsible for the design, development and validation of bioanalytical ligand-binding assays to support pharmacokinetic and toxicity studies in a variety of drug development projects. She received her M.S. degree from the Kazan State University in Russia, her Ph.D. from the N.N. Blokhin Cancer Research Center of the Russian Academy of Medical Sciences in Moscow, Russia, and completed two postdoctoral trainings in immunology at the National Cancer Institute in Frederick, MD and the University of Maryland in Baltimore, MD. Her areas of expertise include cell signaling, innate immunity, immunogenicity and analytical methodology.

Her areas of expertise include cell signaling, innate immunity, immunogenicity and analytical methodology.

Marcelo L. Larramendy, Ph.D., serves as Professor of Molecular Cell Biology at the School of Natural Sciences and Museum (National University of La Plata, Argentina). Appointed Senior Researcher of the National Scientific and Technological Research Council of Argentina. Former Member of the Executive Committee of the Latin American Association of Environmental Mutagenesis, Teratogenesis and Carcinogenesis. Author of more than 470 contributions, including scientific publications, research communications and conferences worldwide. Recipient of several national and international awards. Prof. Larramendy is a regular Lecturer at the international A. Hollaender Courses organized by the IAEMS and former guest scientist at NIH (USA) and University of Helsinki, (Finland). He is expert in Genetic Toxicology and is, or has been, referee for more than 30 international scientific journals. Member of the International Panel of Experts at the International Agency for Research on Cancer (IARC, WHO, Lyon, France) in 2015 for the evaluation of DDT, 2,4-D and Lindane. Presently, Prof. Dr. Larramendy is Head of the Laboratory of Molecular Cytogenetics and Genotoxicology at the UNLP.

Marcelo L. Larramendy’s fields of research interest include genotoxicity, Teratogenesis and Carcinogenesis. His areas of expertise include Molecular Cytogenetcis, Genetic Toxicology and Ecotoxicology.

Professor Kattesh V. Katti is internationally recognized as a leader in the interconnecting fields of—chemistry, radiopharmaceutical sciences, nanotechnology/green nanotechnology and nanomedicine—for biomedical applications, specifically for molecular imaging and therapy of living subjects. The impact of Dr. Katti’s work is widespread, as his pioneering discoveries and strategies, originally developed in his laboratory in bioconjugate chemistry and Nanomedicine, and green nanotechnological tools, are used in many laboratories, industries and hospitals around the world. His contributions in nano and green nanotechnologies have already created a transformative progress in nanomedicine by aiding molecular imaging to help diagnose and manage therapy—all at the cellular levels. Dr. Katti’s ground breaking discoveries in green nanotechnology where he has demonstrated that biocompatible nanoparticles can be produced without the intervention of any toxic chemicals, through phytochemicals of high antioxidant capacities and tumor receptor specificities have created a new generation of molecular imaging and therapeutic nanoceuticals. His approach to green nanotechnology has furthered the scope of holistic and integrative medicine with implications in modulating signaling pathways allowing optimization of therapies targeted to tumor cells/regions without causing adverse toxic effects to normal cells. These original discoveries are expected to have a major impact on how molecular imaging and therapies will eventually be individualized to allow their greater success through theranostic approaches using radioactive nanoparticles, photothermal therapy using targeted nanoparticles and novel therapies involving phytochemicals. Myriad of such approaches developed by Dr. Katti are already impacting clinical translation through comparative oncology in realistic ways as new drugs are being validated for their efficacy in imaging and therapy using tumor bearing dogs where the disease mimics human conditions. In recognition of his original contributions, Dr. Katti has been awarded a number of international awards and citations which include: International Hevesy Medal Award (2015) for excellence in Nuclear Sciences; Elected to the fellowship of the National Academy of Inventors (2015); One of the ‘25 Most Influential Scientists In Molecular Imaging in the World’ award by RT Image, the ‘Father of Green Nanotechnology’ citation by the Nobel Prize Winner Norman Borlaug, Gauss Professorship—Hall of Fame—from the Gottingen Academy of Sciences, ‘Outstanding Scientists Fellows’ award and induction as a Fellow of the Academy of Science, St Louis—one of the oldest scientific academies of the world and many more. In 2013, Dr. Katti was elected as a fellow of the American Association for the Advancement of Science with a citation “for distinguished contributions encompassing nanoscale chemistry, particularly for ground breaking discoveries enabling application of nanotechnology concepts for biomedical applications”. His unprecedented discovery of the production of tumor specific gold nanoparticles through 100% green processes have been cited as the Editor’s choice in Nature, Future Medicine, in Science (AAAS), in Popular Science, by the Discovery Channel and have been highlighted in scientific/medical programs of the British Broadcasting Corporation (BBC, London)

Dr. Katti's research is focused on unraveling fundamentals of science and apply those principles and concepts to developing new chemical species at the macro and nano scales. In the nanodomain, he is interested in exploring chemical, biophysical, magnetic and photophysical properties, that are unique to specific nanoparticulates, toward the design and development of sophisticated diagnostic and therapeutic agents. Targeted nanoparticles are being utilized in the detection of diseases at the cellular/sub cellular levels while radiochemical and X ray absorption properties of gold nanoparticles, embedded selectively within tumor cells/sites, are being applied for effective therapy of breast, liver, lung, oral, prostate and pancreatic cancers. Drug discovery approaches are built around clinical translation motif as Dr. Katti strongly believes that discoveries should translate into value added products to ultimately serve humanity. Green nanotechnology is at the focal point of Dr. Katti's approach to pursuing research in nanotechnology as he strongly believes in the total elimination of toxic chemicals either for the synthesis or as byproducts in the production of engineered nanoparticles. Toward this end, phytochemicals occluded within plants, herbs or from various sources from mother nature are being used in developing 100% green processes for the development of nano constructs for use in a plethora of medical, agricultural, hygienic and technological applications

Ghulam Ahmad Shakeel Ansari is a Professor in the University of Texas Medical Branch, USA. He received his PhD from Aligarh Muslim University in India and post doctoral fellowship from University of Texas Medical Branch in USA. He has more than 120 publications and has written more than 5 book chapters. He also received many honors and awards.

His research interests include molecular toxicology, systems biology, biomarker signatures, metabolomics, analytical toxicology, chemical-mediated autoimmunity and chemical-mediated liver injury

Dr. Bluth practices clinical pathology. His expertise includes biomarker discovery and utility, transfusion medicine, artificial blood/blood alternatives, and translational medicine and commercialization. Dr. Bluth is specifically responsible for the transfusion service.

Dr. Bluth�s research interests covers a broad scope including immunology/inflammation, pancreatology, biomarker discovery, glycolipid based anti-inflammatory therapy, role of IgE in viral diseases and cancer, and blood derived stem cell propogation. Dr. Bluth is responsible for the education and training involved in the medical, basic science and translational research in the department. In addition to scholarly peer-reviewed publications, Dr. Bluth served as an Associate Editor of McPherson and Pincus: Henry�s Clinical Diagnosis and Management by Laboratory Methods (for 21st Ed and 22nd ed). He is the Editor in chief/founding editor of the Journal of Pharmacogenomics and Personalized Medicine and the Journal of Blood Medicine (Dove Medical Press � Auckland, New Zealand).

Dr. Burton Altura is currently serving as Professor of Medicine at New York University School of Medicine, USA

Role of magnesium, sphingolipids and lipid messengers in vascular biology and disease processes, such as stroke, diabetes mellitus and atherogenesis

Dr Chuanshu Huang is currently Professor, Department of Environmental Medicine;Professor, Department of Biochemistry and Molecular Pharmacology Environmental Medicine Environmental Medicine Deputy Director

Signal transduction involved in cellular function, tumor promotion and nutrient chemo-prevention. Reactive oxygen species (ROS) involved in cellular signaling and cancer development . Molecular mechanism of anti-cancer nutrients; Environment and carcinogenesis; |Signal transduction involved in cellular function, tumor promotion and nutrient chemo-prevention. Reactive oxygen species (ROS) involved in cellular signaling and cancer development . Molecular mechanism of anti-cancer nutrients; Environment and carcinogenesis; |Signal transduction involved in cellular function, tumor promotion and nutrient chemo-prevention. Reactive oxygen species (ROS) involved in cellular signaling and cancer development . Molecular mechanism of anti-cancer nutrients; Environment and carcinogenesis; |Signal transduction involved in cellular function, tumor promotion and nutrient chemo-prevention. Reactive oxygen species (ROS) involved in cellular signaling and cancer development . Molecular mechanism of anti-cancer nutrients; Environment and carcinogenesis;

Dr. Hein serves as Peter K. Knoefel Endowed Chair of Pharmacology, Professor and Chairman of the Department of Pharmacology & Toxicology, Distinguished University Scholar, and Vice Provost for Academic Strategy at the University of Louisville. He also directs the National Cancer Institute-funded Cancer Education Program. Dr. Hein previously served as the founding director of the NIH Minority Biomedical Research Support Program at Morehouse School of Medicine and the NIEHS T32 pre- and post-doctoral training program in environmental health sciences at the University of Louisville. He chaired Departments of Pharmacology & Toxicology at Morehouse School of Medicine and the University of North Dakota School of Medicine and Health Sciences prior to his recruitment to the University of Louisville in 1997. Dr. Hein has led development and implementation of pharmacology and toxicology PhD partnerships with Wenzhou Medical University, Jilin University, Cairo University and Ain Shams University. Numerous students have completed thesis and dissertation research training in his laboratory and he contributes towards instruction of undergraduate, graduate and health professional students.

Dr. Hein’s research program includes studies of the molecular epidemiology of cancer susceptibility, pharmacogenetics, genomics, personalized medicine, and functional genomics. Our research in molecular epidemiology identifies individuals genetically susceptible to the development of cancer from environmental and occupational chemicals in order to focus treatment and prevention public health strategies on those at greatest risk. His research in pharmacogenetics/genomics and personalized medicine improves our understanding of the genetic causes for drug failure and/or drug toxicity in order to optimize clinical drug therapy for each individual patient. His research in functional genomics improves understanding of the mechanistic and clinical consequences of genetic variation in the biotransformation of carcinogens and drugs. Dr. Hein has coauthored over 225 peer-reviewed journal articles and book chapters, 75 published gene sequences, and about 600 abstracts. The publications have over 12,000 citations with an h-index 53. Dr. Hein serves as director of funded training programs in environmental health sciences and cancer for pre-doctoral, post-doctoral, undergraduate and professional students. In addition, he has served as principal investigator/co-investigator/mentor on over 75 grants and contracts totaling over $50M.

Dr. Youyang Zhao is a Professor of Pharmacology at the University of Illinois at Chicago (UIC). He has completed his B.S. from Fudan University and Ph.D. from Shanghai Institute of Biochemistry, the Chinese Academy of Sciences, and received his postdoc training in cardiovascular biology at Harvard University and UCSD. Prior to his tenure at UIC, Dr. Zhao was a Senior Research Scientist in cardiovascular drug discovery in Pharmacia/Pfizer Inc. Dr. Zhao's research is focused on lung and vascular biology to delineate the molecular mechanisms of endothelial regeneration and resolution of inflammatory injury, as well as pulmonary vascular remodeling in the pathogenesis of pulmonary arterial hypertension (PAH), and thereby to provide novel druggable targets and therapeutic strategies for treatment of acute respiratory distress syndrome and PAH. Dr. Zhao has published many papers in top-tier journals such as Nat Med, PNAS, J Clin Invest, J Exp Med and Circulation. His lab is well-funded with multiple R01 grants and PPG grant from NIH. Dr. Zhao has served as a reviewer for NIH, DOD, and AHA grant applications and many journals.

Recovery of endothelial barrier integrity after vascular injury is vital for endothelial homeostasis and resolution of inflammation. Endothelial dysfunction plays a critical role in the initiation and progression of vascular diseases such as acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) and atherosclerosis. A part of the research in the lab, employing genetically modified mouse models of human diseases, endothelial progentior cells/stem cells, and translational research approach as well as nanomedicine, is to elucidate the molecular mechanisms of endothelial regeneration and resolution of inflammatory injury and determine how aging and epigenetics regulate these processes (J Clin Invest 2006, 116:2333; J Exp Med 2010, 207:1675; Circulation 2016, 133:2447). We are also studying the role of endothelial cells in regulating macrophage functional polarization and resolving inflammatory lung injury. These studies will identify druggable targets leading to novel therapeutic strategies to activate the intrinsic endothelial regeneration program to restore endothelial barrier integrity and reverse edema formation for the prevention and treatment of ARDs in patients. Pulmonary hypertension is a progressive disease with poor prognosis and high mortality. We are currently investigating the molecular basis underlying the pathogenesis. We have recently identified the first mouse model of PAH with obliterative vascular remodeling including vascular occlusion and formation of plexiform-like lesions resembling the pathology of clinical PAH (Circulation 2016, 133:2447). Our previous studies also show the critical role of oxidative/nitrative stress in the pathogenesis of PAH as seen in patients (PNAS 2002, 99:11375; J Clin Invest 2009, 119:2009), With these unique models and lung tissue and cells from IPAH patients, we will define the molecular and cellular mechanisms underlying severe vascular remodeling and provide novel therapeutic approaches for this devastating disease.

Hari Shanker Sharma, Director of Research (International Experimental Central Nervous System Injury & Repair, IECNSIR), University Hospital, Uppsala University is Professor of Neurobiology (MRC), Docent in Neuroanatomy (UU) and is currently affiliated with Department of Surgical Sciences, Division of Anesthesiology and Intensive Care Medicine, Uppsala University, Sweden. Hari Sharma was born on January 15, 1955 in an Industrialist town Dalmianagar (Bihar), India. He did his Bachelor of Science with Honors from the prestigious L. S. College Muzaffarpur in 1973 and secured 1st position in his batch. He obtained his Master Degree from Bihar University with special expertise in Cell Biology in 1976 and awarded Gold Medal of Bihar University for securing 1st potion in the 1st Class. Hari Sharma joined the group of Professor Prasanta Kumar Dey, a neurophysiologist by training in the Department of Physiology, Institute of Medical; Sciences, Banaras Hindu University, Varanasi in 1977 to obtain Doctor of Philosophy Degree (D.Phil.) in Neurosciences and was awarded Ph.D. in 1982 on “Blood-Brain Barrier in Stress.” Hari Sharma after carrying out a series of Government of India funded Research Projects on the BBB and brain dysfunction (1982–1987), joined the lab of Neuropathology at Uppsala University with Professor Yngve Olsson in 1988 to investigate passage of tracer transport across the BBB caused by stress or traumatic insults to the Brain and Spinal cord at light and electron microscopy. Dr. Sharma awarded the prestigious Alexander von Humboldt Foundation Fellowship of German Government (1989–1991) to work on hyperthermia induced BBB dysfunction at the ultrastructural level in the laboratory of Professor Jorge Cervós-Navarro (a living “Legend in Neuropathology in Europe”). Dr. Sharma joined again Uppsala University and established a network of collaboration on “Experimental CNS Injury Research Group” as a lead investigator with eminent collaborators in various parts of Europe, USA, and Australia (1991–). On his work on hyperthermia Dr. Sharma received the prestigious Neuroanatomy award “Rönnows Research prize” of Uppsala University for “best neuroanatomical research of the year 1996” followed by the Award of the Degree of Doctor of Medical Sciences of Uppsala University in Neuroanatomy in 1999 and selected for the Best Thesis Award of the Medical faculty, “The Hwassers Prize” of 1999. On his meticulous works on the Blood Brain barrier and Brain edema (2000–2003) Dr. Sharma earned the prestigious title of “Docent in Neuroanatomy” of Medical Faculty, Uppsala University in April 2004. Currently his main research interest is Neuroprotection and Neuroregeneration, in relation to the Blood-brain barrier in stress, trauma, and drugs of abuse in health and disease. Dr. Sharma on his research on brain pathology and neuroprotection in different models received the prestigious awards from The Laerdal Foundation of Acute Medicine, Stavanger, Norway, in 2005 followed by Distinguished International Scientists Collaboration Award by National Institute on Drug Abuse (NIDA), Baltimore, MD (2006–2008). His recent work on 5-HT3 receptor mediated neuroprotection in morphine withdrawal induced neurotoxicity won the coveted prize of Best Investigator Award 2008 and Best Scientific Presentation by European Federation of the International Association for Study of Pain (ISAP), and Awarded during their VI Annual Meeting in Lisbon, September 9–12, 2008. His recent research is aimed to find out the role of nanoparticles in Neurodegeneration and Neuroprotection using various treatment strategies that is supported by European Aerospace Research and Development (EOARD), London, UK and US Air Force Research Laboratory, Wright Patterson Air Force Base, Dayton, Oh, USA. On his works on Blood–brain barrier in hypertension and diabetes together with Romanian colleagues, University of Medicine and Pharmacy “Iuliu Hatieganu,” Cluj-Napoca, Romania awarded Dr. Sharma with Honorary Doctorate of Medical Sciences in 2009. Dr. Sharma’s work over 30 years on the blood-brain barrier and brain edema won him the US Neurosurgeon Dr. Anthony Marmarou Award (2011) by the International Brain Edema Society at their 15th Congress in Tokyo, Japan, November 20–24, 2011. His works on Nanoneuroscience and development of nanomedicine to treat the CNS injuries has won accolades at various Government and International Scotties or Organization across the World. Accordingly Dr Sharma was decorated with the most prestigious “Hind Rattan Award 2012” (Jewel of India) on the eve of Republic Day of India 25th January 2012 and Mahatma Gandhi Pravasi Gold Medal on October 12, 2012 in House of Lords, London, UK. Based on his outstanding contribution in Nanoneuropharmacology and nanodrug delivery to treat central nervous system (CNS) diseases including Neurodegenerative diseases such as Alzheimer’s and Parkinson’s Hari Sharma bestowed with Prestigious Gujarat Govt. International Visionary Award 2012 in a glittering function in Ahmedabad, Gujarat on Nov 23, 2012. His further research on co-morbidity factors e.g., hypertension or diabetes may alter pathophysiology of brain injuries and require higher drug dose or nanodrug delivery of neuroprotective agents to minimize brain dysfunction is recognized by Govt. of India by presenting him one of the coveted “Bharat Jyoti Award 2013” (Glory of India) by His Excellency Governor Balmiki Prasad Singh in Hotel Le Meridien, New Delhi on Jan 12, 2013. Dr Sharma also received the highest Award of the Govt. of India “Navrattan Award 2013” (Nine Jewels of India) on the eve of 64th Republic Day of India (25th January 2013) by His Excellency Governor Bhishma Narain Singh, in Ashok Hotel, New Delhi. Hari Sharma is Founding President of the Global College of Neuroprotection & Neuroregeneration (2004-); Elected President of International Association of Neurorestoratology (IANR) (2014-); and selected Senior Expert of Asia-Pacific CEO Association, Worldwide (APCEO) (2012-) for his contribution to uplift scientific research in many countries Globally that may have better economic and social benefit for the mankind. Hari Sharma awarded coveted National Award “Sword of Honor” 2015 by Govt. of India on the eve of 66th Republic Day of India 25th January 2015 in New Delhi Eros Hotel International during the 34th Non-resident Indian (NRI) conclave by Speaker of Lok Sabha (Indian Parliament) the Hon’ble Mrs Meira Kumar of Indian national Congress (INC) Party for the continued extraordinary achievement in nanomedicine for public health awareness and possible therapeutic measures. Based on his expertise in Nanoneuroscience, Hari Sharma was also invited to organize and chair Nanosymposium in Society for Neuroscience meetings in Chicago (2009), San Diego (2010), Washington DC (2011), New Orleans (2012), San Diego (2013) and Washington DC (2014, Nov 15-19, 2014); Chair Neurobiology Symposium 14th Int. Amino Acid & Peptide, Vienna, Austria; Keynote speaker & Chair Nanotechnology-2015, Frankfurt, Germany. Hari Sharma is also the recipient of Prestigious US TechConnect Global Innovation Award 2013 at the National Innovation Summit & Innovation Showcase, Washington DC May 12-16, 2013 on his work on Nanowired cerebrolysin in Neuropathic Pain. Hari Sharma Served as one of the Poster Judges in 2014 180th Annual Meeting of American Association of Advancement of Science (AAAS) Held in Chicago, IL, USA Feb 13-17, 2014 followed by 181st Annual Meeting of American Association of Advancement of Science (AAAS) held in San José, CA, USA Feb 12-16, 2015. Hari Sharma has published over 350 research papers and 85 reviews, 14 monographs, and 80 international book chapters and edited 18 book volumes with Current H-index = 38 (ISI Database) as of today. He served as Guest Editor of Curr. Pharm. Desig. (2005, 2007, 2010–); J Neural. Transmiss. (2006, 2011–) and is the founding Editor-in-Chief of Int. J. Neuroprotec. Neuroregen. (2004–), UK and the European Editor of Central Nervous system-Neurological Disorders Drug Target (2013-). Dr. Sharma is on board of various International Journals including CNS and Neurological Disorders-Drug Targets, USA (2010), Journal of Neurodegeneration and Regeneration, USA (2009–); Austin Journal of Nanomedicine & Nanotechnology (2014-); and is associate editor of Journal of Nanoscience and Nanotechnology (Nanoneuroscience 2006–), USA, Review Editor—Frontiers in Neuroengineering (2007–), Frontiers in Neurorestoratology, and Associate Editor of Frontiers in Aging Neuroscience (2008–), Frontiers of Fractal Physiology (2010–), Switzerland, Journal of Neurorestoratology, Dove Medical press, London, UK (2012–), WebMD Central, Neurology Faculty, Advisory Board Member (2010–), World Journal of Pharmacology (2011–), Journal of Physical Medicine and Rehabilitation, USA (2012–). Dr. Sharma served as volume editor of several progress in Brain research series (Volumes 104, 115, 162 and 180), International review of Neurobiology (Volume 82 and 102) and other Springer Volumes on Spinal cord injury (1988) and Handbook of Neurochemistry (2009) apart from stand alone books (Elsevier, Springer and Academic Press since 1994). Dr. Hari Sharma is invited to join several National Academies of repute including New York Academy fo Science, USA (since 1994–); International Academy of Stress, New York (2003–), Swedish Academy of Pharmaceutical Sciences (2010–). Dr. Sharma has served as an expert evaluator and advisor to various Boards, Councils and Institutions for their Research Grants including Wellcome Trust, London, UK (2011–); Catalan Agency for Health Information and Quality, TV3 (2010–), European Commission Projects (2002–), European Nanomed Council (2009–), Ministry of Health Science Foundation; Medical research Council and University Commission of Grants in various countries in Europe, USA, UK, Canada, Hong Kong, Singapore and in Australia. Some of the notable organizations include: Australia and New Zealand Health Council (2000–); University Commission of Grants, Hong Kong (2002–), Singapore Medical Council, Singapore (2003–); UK Charity Organization “Research on Ageing: Help the Aged” (2003–); Euro Nanomed (2010–). Dr. Sharma is designated as ambassador of the City of Uppsala 2007, by Uppsala County administration and Uppsala Tourism for promoting Uppsala, Sweden as International Research Collaboration/Meetings and Conference Destination. Dr. Hari Sharma is married to Aruna Sharma (nee Bajpai) since 23rd April 1979 and has two sons. Dr Sharma is designated as Visiting Professor, University of Basque Country, Bilbao, Spain supported by Basque Govt. Foundation. His political affiliation belongs to Swedish Social Democrat Party (Socialdemokraterna, Sverige) where he is associated with the development of Education and Research matters in Sweden actively

Nanoneuroscience, Nanoneuropharmacology and nanodrug delivery

Burton M Altura is a Professor at Suny Downstate Medical Center in USA. He received his PhD from New york University School of Medicine in the year 1964. He serves as an Ad Hoc Reviewer and also reviewer for various journals and funding organizations.His research interests include the role of magnesium, sphingolipids and lipid messengers in vascular biology and disease processes, such as stroke, diabetes mellitus and atherogenesis. An additional major interest is the role of alcohol and substances of abuse in stroke etiology.

role of magnesium, sphingolipids and lipid messengers in vascular biology and disease processes, such as stroke, diabetes mellitus and atherogenesis. An additional major interest is the role of alcohol and substances of abuse in stroke etiology.

Dr. Ahmet Aydın has done his BA in 1987, MS in 1992 and completed PhD in 1999

Oxidative stress and antioxidant system, Trace elements and heavy metal toxicity, Biocompatibility of medical devices, toxicity tests, Risk assessment, Drug development

Dr. Luo been studying molecular pathology related to human malignancies in the last 24 years. Currently, he is a Professor of Pathology and Director of High Throughput Genome Center at University of Pittsburgh. In the last 16 years, Dr. Luo has been largely focusing on genetic and molecular mechanism of human prostate and hepatocellular carcinomas. In this period, his group has identified and characterized several genes that are related to prostate cancer and hepatocellular carcinoma, including SAPC, myopodin, CSR1, GPx3, ITGA7, MCM7, MT1h and GPC3. He has characterized several signaling pathways that play critical role in prostate cancer development, including Myopodin-ILK-MCM7 inhibitory signaling, myopodin-zyxin motility inhibition pathway, CSR1-CPSF3, CSR1-SF3A3 and CSR1-XIAP apoptotic pathways, MT1h-EHMT1 egigenomic signaling, ITGA7-HtrA2 tumor suppression pathway, GPx3-PIG3 cell death pathway, AR-MCM7 and MCM7-SF3B3 oncogenic pathways. He proposed prostate cancer field effect in 2002. He is one of the pioneers in utilizing high throughput gene expression and genome analyses to analyze field effects in prostate cancer and liver cancer. He is also the first in using methylation array and whole genome methylation sequencing to analyze prostate cancer. Recently, Dr. Luo’s group found that patterns of copy number variants of certain specific genome loci are predictive of prostate cancer clinical outcomes, regardless tissue origin. His discovery of several novel fusion transcripts and their association with aggressive prostate cancer has brought significant new insight into the field of prostate cancer research. Overall, these findings advance our understanding on how cancer develops and behaves, and lay down the foundation for better future diagnosis and treatment of human malignancies.

Currently, Dr. Luo's research interests involve identifying new tumor suppressor genes and tumor markers in several human malignancies such as prostate cancer, hepatocellular carcinoma, etc. Subsequently, we will direct our effort to evaluate the prognostic values of these genes and markers in making early diagnosis of prostate cancer and serving as drug targets for cancer prevention programs.

Dr. Karen G.Mulkijanyan currently holds positions of Head of the Department of Preclinical Pharmacological Research at Tbilisi State Medical University (TSMU) I.Kutateladze Institute of Pharmacochemistry and full Professor at the Caucasus International University Faculty of Medicine He obtained MS in Biochemistry in 1981, and PhD in Pharmacy in 2005. Dr. Mulkijanyan was a manager/ key investigator of research projects funded by CRDF Global/GRDF, STCU, GNSF/SRSNF. As Organizing Committee Member, he arranged several international congresses and conferences on pharmacology and pharmacy. Dr. K.Mulkijanyan co-authored more than 100 scientific publications, 30 presentations at international scientific meetings and 2 patents in pharmacology. Dr. K.Mulkijanyan is Founder and President of the Georgian Association for Laboratory Animal Science, a member of the Association of Professional Chemists of Georgia and Association of University Technology Managers.

Pharmacology of anti-inflammatory, ulcer preventive, burn and wound healing drugs; analysis of structure-activity relationship (SAR) and prediction of bioactivity of natural, modified and synthesized compounds; intellectual property protection; technology transfer and technology commercialization, use and care of laboratory animals.

Dr. Bluth practices clinical pathology. His expertise includes biomarker discovery and utility, transfusion medicine, artificial blood/blood alternatives, and translational medicine and commercialization. Dr. Bluth is specifically responsible for the transfusion service.

Dr. Bluths research interests covers a broad scope including immunology/inflammation, pancreatology, biomarker discovery, glycolipid based anti-inflammatory therapy, role of IgE in viral diseases and cancer, and blood derived stem cell propogation. Dr. Bluth is responsible for the education and training involved in the medical, basic science and translational research in the department. In addition to scholarly peer-reviewed publications, Dr. Bluth served as an Associate Editor of McPherson and Pincus: Henrys Clinical Diagnosis and Management by Laboratory Methods (for 21st Ed and 22nd ed). He is the Editor in chief/founding editor of the Journal of Pharmacogenomics and Personalized Medicine and the Journal of Blood Medicine (Dove Medical Press Auckland, New Zealand).

Professor Ewa L Gregoraszczuk is specialized in reproductive toxicology as well as hormone dependent cancer. She has graduated from Jagiellonian University in Krakow, Poland. From 1998 full professor of endocrinology, initiator and Head of Department of Physiology and Toxicology of Reproduction. She has authored 183 peer-reviewed articles in leading journals such as Reproductive Toxicology, Toxicology, Toxicology Letters, Chemosphere, Human and Experimental Toxicology, Xenobiotica, Environmental Toxicology and Pharmacology, Journal of Applied Toxicology, Toxicology and Industrial Health, Environment International, Journal of Environmental Science and Health. Member of Polish Endocrinology Society, International Society of Endocrinology (ISE), The New York Academy of Sciences, The European Tissue Culture Society. Promotor 60 MD, 16 PhD and 3 habilitation She has cooperation with several international group of sciences including Food Science and Nutrition, The Hebrew University of Jerusalem, Rehovot, Israel, Department of Veterinary Biosciences, Univeristy of Illinois, at Urbana-Champaign, USA, Graduate Center for Toxicology, Univeristy of Kentucky, at Lexington, USA, Institute of Public Health in Ostrava, National Reference Laboratory for Analysis of POPs Ministry of Health CR, Czech Republic. Was invited as a reviewer in Reproductive Toxicology, Toxicology, Toxicology Letters, Chemosphere, Human and Experimental Toxicology, Xenobiotica, Environmental Toxicology and Pharmacology, Journal of Applied Toxicology, Drug and Chemical Toxicology, Food and Chemical Toxicology, Xenobiotica, Toxicological Sciences and other.

The effects of different single and mixture of endocrine compounds in hormone dependent tissue such as: ovary, placenta. Cancerogenic action of endocrine disruptors in breast and ovarian tissue.

Dr Rana Jaffer is an Emergency Medicine Consultant, working at Hamad Medical Corporation in Doha, Qatar. She has completed her medical school from Aden University, Yemen, followed by residency in Emergency Medicine from Arab Board of Medical Specialties. She is a Member of the Royal College of Emergency Medicine, UK. Further, she has completed Post Graduate Diploma in Toxicology from Cardiff University, UK. She is an active member of the Toxicology Team at her hospital besides being a faculty member at Emergency Medicine Residency Teaching program at Hamad Hospital and at Qatar University. Her professional focus has always been to teach Emergency Medicine and Toxicology to residency students and improve their skills for better patient care. She has special interest in talking about Khat abuse (Catha Edulis) which is a common practice in the middle-east and North Africa. She thinks a conference is a good media for sharing knowledge and cultures from different parts of the world

Toxicology

Dr. Paula Moyano received his JD degree at the Complutense University of Madrid in 2013. She has worked in the University of Massachusetts’ Students Legal Services Office, while living in Massachusetts in 2011. She received a Masters in Pedagogical Sciences in 2017. She specialized in neurotoxicology and legal sciences and received his PhD in Toxicology and legal medicine in 2016. She is a member of the Complutense University’s Research Team EcoBioTox. She is co-author of several publications on toxicology and environmental journals and participated as a co-author of two chapters of the book Thyroid Toxicity.

Dr. Moyano research focuses on the evaluation of the effects of environmental pollutants in the development of neurodegenerative diseases. Her area of expertise are toxicogenomics, since her research looks into the toxic effects at genomic levels of persistent environmental chemicals and pollutants, and regulatory toxicology, since her interest lies in promoting changes at regulatory level of the maximum allowed levels of exposure to the substances that she studies.

Dr. Javier Del Pino is Associate Professor at the Department of Pharmacology and Toxicology, University Complutense of Madrid, Spain from 2016. He received his PharmD degree at the University Complutense University of Madrid in 2004. He has two Masters in Sciences 2009 and 2010. He worked in Institute of Health Carlos III in the National Center of Environmental Health. From 2010 to 2012 he was an Associated Researcher at University of Massachusetts (UMASS) working in Sandra Petersen´s Lab in a National Institute of Health (NIH) project on developmental effects of TCDD endocrine disruptor on sexual differentiation. He specialized in neurotoxicology and neurodevelopmental toxicology and received his PhD in Toxicology in 2009. He is a member and Manager of the Complutense University’s Research Team EcoBioTox. He is co-author of several publications on toxicology and environmental journals and participated as a co-author of toxicology Book´s chapters.

Dr. Del Pino research focuses on the evaluation of the effects of environmental pollutants in the development of neurodegenerative diseases. His area of expertise are neurotoxicology, citotoxicity and toxicogenomics, since his research deepens into the toxic effects of metals and biocides that induce cognitive disorders and other neurodegenerative processes both at cellular and tissue level, studying the molecular mechanisms involved in these effects. He takes a special interest of the genomic toxic effects that metals and biocides produce and the levels from which these effects are produced, all related to safety evaluation of these compounds.

Simona Clichici is associate professor at the Department of Physiology, University of Medicine and Pharmacy “Iuliu Haţieganu”, Cluj-Napoca, Romania. She is the coordinator of the In Vivo Research Laboratory at this Physiology Department. She has practical experience and many published papers concerning in vivo experimental design of different pathological conditions, oxidative stress and cytotoxicity assessment, study of the nanomaterials effects on living organisms, protective effects of different natural compounds, photodynamic therapy and carcinogenesis. She was the coordinator of 2 national grants regarding toxicological studies and she is the author/co-author of 45 ISI papers, all of them concerning experimental and toxicological studies on lab animals.

Simona Clichici’s mainly focuses her research work upon In Vivo technologies. She has also published many papers concerning in vivo experimental design of different pathological conditions, oxidative stress and cytotoxicity assessment, study of the nanomaterials effects on living organisms, protective effects of different natural compounds, photodynamic therapy and carcinogenesis.

Biography& Publications-DR Swamy KB Swamy K B, presently working as Professor& HOD of Clinical Anatomy, Lincoln University, Kuala Lumpur, MALAYSIA, has been awarded PhD by Andhra University, India. He has taken his Master’s Degree MS (in Clinical Anatomy) from Andhra Medical College, India, DMCh (Maternal & Child Health) from IGNOU, New Delhi, his Medical Degree (MBBS) in 1976, He has expertise in Human Genetics, Reproductive & Developmental Anatomy and also in Herbal Medicine. He has been the genetic counselor for many institutions, with prestigious grants (FRGS,,URGS) from Malaysian Government, he has conducted many researches on Herbal Medicine and Diabetes, on “Brain size and Intelligence Quotient (IQ)”, He has been the former founder Anatomist, Professor and Head of the Department for many Medical Schools in India as well as in Malaysia. He is an International Editorial Board Member for many reputed journals like Anatomical Society of India (ASI). Recently he has been unanimously elected as an Executive Board Member for ASI and an Organizing Committee Member for the “9th Euro-Global Summit on Toxicology and Applied Pharmacology held through June 22-24, 2017 at Paris, France., 11th International Conference on Pharmacoepidemiology and Clinical Research October 02-03, 2017 Kuala Lumpur, Malaysia, Editor for many journals like "Novel Techniques in Nutrition and FoodScience". Journal, Herald Scholarly Open Access Journals ( Annals Of anatomy & Physiology), Journal Anatomival Society Of India (JASI) and many more and also Manscript reviewer for journals like “Food & Chemical Toxicolgy (Elseveir), "Novel Techniques in Nutrition and FoodScience" and many more.

He has expertise in multi medical disciplines, Human Genetics, Reproductive Health & Developmental Anatomy and in Herbal Medicine. He has been the genetic counsellor for many Medical institutions. He possess prestigious grants FRGS,URGS from Malaysia, he has conducted researches on Herbal Medicine and Diabetes, “Brain size and Intelligence Quotient (IQ)”,